Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 12.91B P/E 48.82 EPS this Y 6.80% Ern Qtrly Grth -46.20%
Income 168.07M Forward P/E 34.17 EPS next Y 15.30% 50D Avg Chg 1.00%
Sales 1.16B PEG 3.68 EPS past 5Y 11.95% 200D Avg Chg 3.00%
Dividend N/A Price/Book 6.83 EPS next 5Y 11.25% 52W High Chg -16.00%
Recommedations 1.90 Quick Ratio 2.47 Shares Outstanding 158.65M 52W Low Chg 21.00%
Insider Own 1.02% ROA 5.74% Shares Float 156.82M Beta 1.27
Inst Own 100.17% ROE 8.33% Shares Shorted/Prior 3.70M/2.95M Price 82.02
Gross Margin 66.47% Profit Margin 14.50% Avg. Volume 914,012 Target Price 83.32
Oper. Margin 22.44% Earnings Date Oct 29 Volume 1,280,237 Change -0.10%
About Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Bio-Techne Corp News
12/23/24 Bio-Techne Inks New Agreement With Waters Corporation: Stock to Gain?
12/20/24 BIO-TECHNE TO PRESENT AT THE 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
12/19/24 BIO-TECHNE ANNOUNCES BIOTHERAPEUTIC CHARACTERIZATION STRATEGIC CO-MARKETING AND CO-PROMOTION AGREEMENT
12/18/24 ScaleReady awards a G-Rex® Grant to Moonlight Bio
12/12/24 Bio-Techne Launches ESR1 Mutation Monitoring Assay: Stock to Gain?
12/12/24 BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH MEDSANTEK TO EXPAND ACCESS TO PORTFOLIO ACROSS TURKEY
12/10/24 BIO-TECHNE LAUNCHES ESR1 MUTATION MONITORING ASSAY
12/04/24 Can Mixed Financials Have A Negative Impact on Bio-Techne Corporation's 's (NASDAQ:TECH) Current Price Momentum?
12/02/24 Should You Continue to Retain Bio-Techne Stock in Your Portfolio?
11/29/24 Techne (TECH) Up 2.2% Since Last Earnings Report: Can It Continue?
11/27/24 BIO-TECHNE TO PRESENT AT THE CITI 2024 GLOBAL HEALTHCARE CONFERENCE
11/25/24 Gemini Bioproducts, LLC Acquires Selected Fetal Bovine Serum (FBS) Product Rights and Inventory from Bio-Techne
11/20/24 BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH LEADER LIFE SCIENCES
11/18/24 BIO-TECHNE AND ALZpath ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE NEURODEGENERATIVE DISEASE RESEARCH
11/14/24 BIO-TECHNE TO HIGHLIGHT NOVEL SOLUTIONS FOR CANCER AND CARRIER SCREENING AT AMP 2024 ANNUAL MEETING & EXPO
11/11/24 UPDATED: BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS
11/11/24 BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS
11/08/24 BIO-TECHNE TO PRESENT AT INVESTOR CONFERENCES
11/07/24 ScaleReady Announces multiple G-Rex® Grants have been awarded to leading investigators at the Baylor College of Medicine's Center for Cell and Gene Therapy
11/06/24 There May Be Some Bright Spots In Bio-Techne's (NASDAQ:TECH) Earnings
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Kummeth Charles R. Chief Executive Offi.. Chief Executive Officer Jul 21 Sell 88.3628 80,000 7,069,024 1,258,766 07/25/23
Kummeth Charles R. Chief Executive Offi.. Chief Executive Officer Jun 30 Option 26.65 616,676 16,434,415 1,729,493 07/05/23
Kelderman Kim Pres. Diagnostics &.. Pres. Diagnostics & Genom Aug 23 Option 150.78 663 99,967 3,801 08/25/22
Furlow Brenda S. SVP - General Counse.. SVP - General Counsel Aug 08 Option 177.32 563 99,831 6,523 08/10/22
Kummeth Charles R. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Jul 28 Option 108.49 45,346 4,919,588 262,749 08/01/22
Kummeth Charles R. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Jul 06 Option 108.49 50,000 5,424,500 248,338 07/08/22
HIGGINS JOHN L Director Director Jun 07 Option 66.9 1,600 107,040 5,206 06/09/22
HIGGINS JOHN L Director Director Jun 07 Sell 365.2 1,600 584,320 4,606 06/09/22
Kummeth Charles R. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Jun 07 Option 108.49 5,104 553,733 203,442 06/09/22
Kummeth Charles R. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Jun 07 Sell 365 5,104 1,862,960 198,338 06/09/22
BAUMGARTNER ROBERT V Director Director May 10 Buy 352.55 300 105,765 10,106 05/11/22
Hippel James Chief Financial Offi.. Chief Financial Officer Nov 01 Option 125.05 9,022 1,128,201 10,955 11/03/21
Hippel James Chief Financial Offi.. Chief Financial Officer Nov 01 Sell 526.65 9,022 4,751,436 10,755 11/03/21
Furlow Brenda S. SVP - General Counse.. SVP - General Counsel Sep 07 Sell 510.25 6,871 3,505,928 7,620 09/07/21
Furlow Brenda S. SVP - General Counse.. SVP - General Counsel Sep 07 Option 125.05 6,871 859,219 14,491 09/07/21
BAUMGARTNER ROBERT V Director Director Aug 25 Option 87.39 4,000 349,560 13,612 08/25/21
BAUMGARTNER ROBERT V Director Director Aug 25 Sell 485.27 4,000 1,941,080 9,612 08/25/21
Kummeth Charles R. Chief Executive Offi.. Chief Executive Officer Jun 16 Sell 449.6 7,481 3,363,458 166,904 06/16/21
Kummeth Charles R. Chief Executive Offi.. Chief Executive Officer Feb 18 Option 94.35 30,000 2,830,500 176,269 02/18/21
Eansor Norman David President-Protein Sc.. President-Protein Sciences Feb 09 Option 106.59 32,933 3,510,328 34,251 02/09/21
Eansor Norman David President-Protein Sc.. President-Protein Sciences Feb 09 Sell 381.75 32,933 12,572,173 1,318 02/09/21
Hippel James Chief Financial Offi.. Chief Financial Officer Jan 13 Option 106.59 10,000 1,065,900 19,137 01/13/21
Hippel James Chief Financial Offi.. Chief Financial Officer Jan 13 Sell 332.19 10,000 3,321,900 9,137 01/13/21
Furlow Brenda S. SVP - General Counse.. SVP - General Counsel Dec 02 Sell 302.1 10,857 3,279,900 6,124 12/02/20
Furlow Brenda S. SVP - General Counse.. SVP - General Counsel Dec 02 Option 106.59 11,795 1,257,229 16,981 12/02/20
Hippel James Chief Financial Offi.. Chief Financial Officer Nov 12 Option 106.59 10,991 1,171,531 16,528 11/12/20
Hippel James Chief Financial Offi.. Chief Financial Officer Nov 12 Sell 309.14 10,991 3,397,758 9,137 11/12/20
Kummeth Charles R. Chief Executive Offi.. Chief Executive Officer Nov 10 Option 86.25 25,157 2,169,791 186,644 11/10/20
STEER RANDOLPH C Director Director Nov 10 Option 68.63 10,000 686,300 15,112 11/10/20
STEER RANDOLPH C Director Director Nov 10 Sell 301.97 10,000 3,019,700 5,112 11/10/20
HIGGINS JOHN L Director Director Nov 10 Option 70.35 5,000 351,750 9,412 11/10/20
HIGGINS JOHN L Director Director Nov 10 Sell 299.96 5,000 1,499,800 4,412 11/10/20
Hippel James Chief Financial Offi.. Chief Financial Officer Nov 06 Option 108.49 15,909 1,725,967 17,946 11/06/20